{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:49:14Z","timestamp":1782107354701,"version":"3.54.5"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aims to investigate the potential association between 13 disease-modifying immunosuppressive drugs used to treat multiple sclerosis and intervertebral disc herniation, thereby filling a gap in pharmacovigilance research in this field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We extracted adverse event reports from the FAERS database covering 2005 to 2025. Disproportionality analyses using four established algorithms (ROR, PRR, EBGM and IC) with unified predefined thresholds were performed. We also conducted subgroup analyses and explored the temporal characteristics of adverse event onset. Results: Teriflunomide, natalizumab and ocrelizumab have shown positive disproportionality signals for intervertebral disc herniation. And these signals merely reflect statistical associations and do not confirm causality. Among these, men and young-to-middle-aged adults populations presented relatively higher disproportionality signal values. Furthermore, teriflunomide-associated intervertebral disc herniation exhibits characteristics of early-onset risk, whereas there is no clear temporal clustering of events associated with natalizumab and ocrelizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Three medications demonstrated positive disproportionality reporting signals for intervertebral disc herniation, which require further validation. Clinicians are suggested to raise vigilance on spinal adverse events and tailor therapeutic strategies when prescribing these agents for multiple sclerosis management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1877458","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:38:26Z","timestamp":1782106706000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world pharmacovigilance analysis of the association between multiple sclerosis disease-modifying therapies and intervertebral disc herniation"],"prefix":"10.3389","volume":"17","author":[{"given":"Nan","family":"Yang","sequence":"first","affiliation":[{"name":"Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University","place":["Taiyuan, China"]},{"name":"Hospital of China Railway 12th Bureau Group","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[{"name":"Xinqiao Hospital ARMY Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Feng","sequence":"additional","affiliation":[{"name":"Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e200462","DOI":"10.1212\/CPJ.0000000000200462","article-title":"Herpes zoster infections with multiple sclerosis disease-modifying therapies: a real-world pharmacovigilance study","volume":"15","author":"Balshi","year":"2025","journal-title":"Neurol. Clin. Pract."},{"key":"B2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00264-019-04324-y","article-title":"Disc herniation and disc disease: the present and the future of management","volume":"43","author":"Benzakour","year":"2019","journal-title":"Int. Orthop."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1177\/1352458520949986","article-title":"Adverse event profile differences between rituximab and ocrelizumab: findings from the FDA adverse event reporting database","volume":"27","author":"Caldito","year":"2021","journal-title":"Mult. Sclerosis Houndmills, Basingstoke, Engl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e36545","DOI":"10.7759\/cureus.36545","article-title":"A severe disc herniation mimics spinal tumor","volume":"15","author":"Chu","year":"2023","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/brainsci7070078","article-title":"Multiple sclerosis: immunopathology and treatment update","volume":"7","author":"Dargahi","year":"2017","journal-title":"Brain Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e70397","DOI":"10.1111\/ene.70397","article-title":"Recent advances in interventions targeting remyelination and a systematic review of remyelinating effects of approved disease-modifying treatments for multiple sclerosis","volume":"32","author":"De Keersmaecker","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.3390\/ijms21124229","article-title":"Molecular effects of FDA-approved multiple sclerosis drugs on glial cells and neurons of the central nervous system","volume":"21","author":"De Kleijn","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.pop.2015.01.007","article-title":"Multiple sclerosi","volume":"42","author":"Files","year":"2015","journal-title":"Prim. Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"111021","DOI":"10.1016\/j.intimp.2023.111021","article-title":"Ocrelizumab and ofatumumab, but not rituximab, trigger complement induction in vitro","volume":"124","author":"F\u00f8rde","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3174\/ajnr.A2238","article-title":"Measuring myelin repair and axonal loss with diffusion tensor imaging","volume":"32","author":"Fox","year":"2011","journal-title":"AJNR. Am. Journal Neuroradiology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1600-0404.2010.01444.x","article-title":"Pathophysiology of multiple sclerosis and the place of teriflunomide","volume":"124","author":"Gold","year":"2011","journal-title":"Acta Neurol. Scand."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1290666","DOI":"10.3389\/fimmu.2023.1290666","article-title":"Bioavailable central nervous system disease-modifying therapies for multiple sclerosis","volume":"14","author":"Hartung","year":"2023","journal-title":"Front. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ncl.2016.06.016","article-title":"Epidemiology of multiple sclerosis","volume":"34","author":"Howard","year":"2016","journal-title":"Neurol. Clin."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e70055","DOI":"10.1002\/jsp2.70055","article-title":"Analysis of nicotine toxicity and mechanisms of senescence in nucleus pulposus cells using network toxicology and molecular docking technique","volume":"8","author":"Jiang","year":"2025","journal-title":"JOR Spine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00415-025-13134-9","article-title":"Safety and efficacy of teriflunomide on clinical course, and laboratory findings in patients with HTLV-1-associated myelopathy\/tropical spastic paraparesis: a triple-blind study","volume":"272","author":"Jozan","year":"2025","journal-title":"J. Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"123303","DOI":"10.1016\/j.jns.2024.123303","article-title":"Multi-omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis","volume":"467","author":"Kornilov","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1653003","DOI":"10.3389\/fimmu.2025.1653003","article-title":"Integrative pharmacovigilance and AI-based framework uncovers potential drug triggers in juvenile idiopathic arthritis","volume":"16","author":"Luo","year":"2025","journal-title":"Front. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40263-023-00985-x","article-title":"Teriflunomide concentrations in cerebrospinal fluid and plasma in patients with multiple sclerosis: a pharmacokinetic study","volume":"37","author":"Lycke","year":"2023","journal-title":"CNS Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.3390\/jcm11123301","article-title":"Association between occupation and cervical disc degeneration in 1211 asymptomatic subjects","volume":"11","author":"Machino","year":"2022","journal-title":"J. Clin. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","article-title":"Anti-CD20 therapies for multiple sclerosis: current status and future perspectives","volume":"269","author":"Margoni","year":"2022","journal-title":"J. Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","article-title":"Multiple sclerosis: clinical aspects","volume":"31","author":"Oh","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/bcp.12285","article-title":"New and emerging immune-targeted drugs for the treatment of multiple sclerosis","volume":"78","author":"Palmer","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.7224\/1537-2073.2022-080","article-title":"Serum sickness\/serum sickness-like reactions following ocrelizumab infusion in 2 patients with multiple sclerosis","volume":"25","author":"Rjeily","year":"2023","journal-title":"Int. Journal MS Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis","volume":"80","author":"Roos","year":"2023","journal-title":"JAMA Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000491567","article-title":"An FDA-approved drug screen for compounds influencing craniofacial skeletal development and craniosynostosis","volume":"10","author":"Seda","year":"2019","journal-title":"Mol. Syndromol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"17562864241276204","DOI":"10.1177\/17562864241276204","article-title":"Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy","volume":"17","author":"Shirani","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B32","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1503\/cmaj.130727","article-title":"Drug therapy for multiple sclerosis","volume":"186","author":"Tavazzi","year":"2014","journal-title":"CMAJ Can. Med. Assoc. J. = J. de l'Association Medicale Can."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/pm\/pnaa008","article-title":"Myofascial inflammation due to intervertebral disc herniation","volume":"21","author":"Wanderman","year":"2020","journal-title":"Pain Medicine (Malden, Mass.)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1177\/1352458514556296","article-title":"Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF","volume":"21","author":"Warnke","year":"2015","journal-title":"Mult. Sclerosis Houndmills, Basingstoke, Engl."},{"key":"B35","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s13018-025-05854-5","article-title":"Focusing on spinal stenosis: emerging discoveries concerning Alendronate-induced risks and genetic drug targets","volume":"20","author":"Yang","year":"","journal-title":"J. Orthop. Surg. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1186\/s12889-025-23178-1","article-title":"Global burden of low back pain from 1990 to 2021: a comprehensive analysis of risk factors and trends using the global burden of disease study 2021","volume":"25","author":"Yang","year":"","journal-title":"BMC Public Health"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1685289","DOI":"10.3389\/fphar.2025.1685289","article-title":"Evaluating the risk of osteopenia-related adverse events with antiepileptic drugs: a pharmacovigilance study based on the FAERS database","volume":"16","author":"Yang","year":"","journal-title":"Front. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00415-025-13224-8","article-title":"Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study","volume":"272","author":"Zaccone","year":"2025","journal-title":"J. Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1622339","DOI":"10.3389\/fphar.2025.1622339","article-title":"Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1877458\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:38:27Z","timestamp":1782106707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1877458\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":39,"alternative-id":["10.3389\/fphar.2026.1877458"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1877458","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1877458"}}